Microglia are the resident immune cell of the central nervous system (CNS), and serve to protect and maintain the local brain environment. Microglia are critically dependent on signaling through the colony-stimulating factor 1 receptor (CSF1R); administration of CSF1R inhibitors that cross the blood brain barrier (BBB) lead to the elimination of up to 99% of microglia, depending on CNS exposure and treatment duration. Once microglia are depleted, withdrawal of inhibitor stimulates repopulation of the entire CNS with new cells, conceivably enabling a therapeutic strategy for beneficial renewal of the entire microglial tissue. We have explored the kinetics and limits of this repopulation event and show that the rate of microglial repopulation is proportional to the extent of microglial depletion -greater depletion of microglia results in more rapid repopulation. Using a CSF1R inhibitor formulation that eliminates approximately 99% of microglia within 7 days, we subjected mice to multiple rounds of elimination (7 days' treatment) and repopulation (7 days' recovery) and found that the brain only has the capacity for a single complete repopulation event; subsequent elimination and CSF1R inhibitor withdrawal fail to repopulate the brain. However, if the recovery time between, or after, cycles is extended sufficiently then the brain can ultimately repopulate. These kinetic studies define the opportunities and possible limits of the remarkable renewal capacities of microglia.
| INTRODUCTION
Microglia are the primary innate immune cells of the central nervous system (CNS), capable of sensing and responding to insults in the local environment (Nimmerjahn, Kirchhoff, & Helmchen, 2005) . During development, they also have a crucial role in synaptic sculpting (Paolicelli et al., 2011; Schafer et al., 2012) , as well as regulation of neurogenesis (Antony, Paquin, Nutt, Kaplan, & Miller, 2011) ; this function is maintained in the adult brain, where they continue to regulate neuronal structures and connections (Rice et al., 2015; Rice et al., 2017; Tremblay, Lowery, & Majewska, 2010) . Unique among myeloid cell types, microglia directly derive from yolk sac macrophage precursors, and colonize the CNS early in development (Ginhoux et al., 2010; Hoeffel et al., 2015) . Due to the presence of the blood brain barrier (BBB), microglia are separated from myeloid cell populations in the periphery, and are long-lived and self-sustaining in their isolation (Lawson, Perry, & Gordon, 1992 ).
We previously discovered that microglia are dependent upon signaling through the colony-stimulating factor 1 receptor (CSF1R) for their survival (Elmore et al., 2014) . Administration of BBB-permeant CSF1R inhibitors leads to the rapid elimination of up to 99% of microglia in a dose-dependent fashion (Dagher et al., 2015) . Microglia can be depleted for the duration of CSF1R inhibitor administration, but withdrawal of inhibitors from the microglia-depleted brain stimulates rapid repopulation, which occurs from proliferation of cells contained within the CNS (Elmore et al., 2014; Huang et al., 2018) . Overall, within approximately 14 days of inhibitor withdrawal, the CNS is fully repopulated with similar microglia densities, spacing, and morphologies to controls (Elmore, Lee, West, & Green, 2015) . Similar repopulation kinetics have been reported in an alternative model of microglial depletion (Bruttger et al., 2015) utilizing an acute administration of diphtheria toxin, which also confirmed that repopulation occurred from within the CNS. These studies show that the adult brain has a remarkable capacity to repopulate the entire microglial tissue and gives insights into the regulation of microglial homeostasis and inflammatory responses.
Microglial elimination via CSF1R inhibitors has been shown to have wide ranging beneficial effects in various CNS disease models (Asai et al., 2015; Han, Harris, & Zhang, 2017; Janova et al., 2017; Klein et al., 2015; Schreiner et al., 2015; Spangenberg et al., 2016; Valdearcos et al., 2014) , while depletion followed by repopulation in injured mice leads to resolution of chronic inflammatory responses, and promotes recovery (Rice et al., 2017) . As such, CSF1R inhibitors are an attractive drug target for any disease characterized by neuroinflammation and microgliosis. This is further validated by the current clinical utility of CSF1R inhibitors (i.e. Tap et al., 2015) including a clinical trial demonstrating that CSF1R inhibitors also reduce microglia numbers in human brains (Butowski et al., 2016) . Thus, it is imperative that we understand the consequences, kinetics, and capacity of the adult brain for microglial depletion and repopulation. Crucially, we find that the adult brain appears to only have the capacity for a single repopulation event, after which "normal" repopulation then fails to occur. However, if the recovery time between, or after, cycles is extended, then the brain can ultimately repopulate, suggesting an alteration in the mechanism or source of the cells that contribute to the new myeloid tissue. These findings help to define the complexities of myeloid repopulation and regulation in the adult brain. 
| MATERIALS AND METHODS

| Compounds
| Animal treatments
All rodent experiments were performed in accordance with animal protocols approved by the Institutional Animal Care and Use Committee at the University of California, Irvine. 2-9-month-old age-matched male C57Bl/6J wild-type or CX3CR1-GFP +/− mice were provided with control chow or PLX3397 chow for 7 days at a time, for one to three cycles of treatment. Following each treatment cycle, PLX3397 was withdrawn and all mice maintained on control chow for 7 or 28 days. platelet-derived growth factor receptor alpha-cyclic recombi- 
| Confocal microscopy
Fluorescent immunolabeling followed a standard indirect technique (primary antibody followed by fluorescent secondary antibody), as previously described (Elmore et al., 2014 
| Statistics
One-way analysis of variances (ANOVAs) consistent with repopulation results from mice after being treated for 3 weeks with 290 ppm PLX3397, which led to a 95% depletion of microglia (Elmore et al., 2014) . Comparing this rate of repopulation with that observed after 50% microglial depletion, it is apparent that repopulation is much more rapid and complete with higher levels of microglial depletion.
| A restricted capacity for microglial repopulation with repeated short cycles of thorough depletion
Having now identified a formulation of PLX3397 that potently eliminates~99% of microglia within 7 days, we set out to determine whether there might be a finite capacity for repopulation with nearcomplete elimination cycles. To that end, we subjected 2-month-old male wild-type mice to three cycles of elimination and repopulation with PLX3397 at 600 ppm in chow (7 days on drug, 7 days off drug per cycle; n = 4/group; Figure 2a ). Microglia were robustly eliminated for all three cycles, but repopulation was only observed in the first cycle (Figure 2b ,c), with very few cells repopulating in Cycles 2 and 3. PK data show that PLX3397 is rapidly washed out from both the plasma and brain, and that it does not accumulate with each progressive cycle ( Figure 2d ). Thus, the lack of repopulation in the second and third cycle is not due to accumulation of PLX3397.
These results show that within these 7-day cycles, the adult brain has a restricted capacity for myeloid repopulation and appears to only have sufficient pools available for one complete repopulation event.
| Transcriptome analyses of microglia depleted and repopulated brains
To explore the consequences and signaling pathways that were affected by microglial depletion, repopulation, and failed (Figure 3f,g ).
In further exploring gene expression changes in non-microglial cells, we found that OPC genes were downregulated by microglial depletion, in line with recent reports that depletion lowers OPC 
| Expanded capacity for myeloid cell repopulation with increased recovery time
Having shown that when challenged with short cycles of thorough microglial depletion the adult brain is limited to one complete round of microglial repopulation, we wanted to determine if the myeloid cell repopulation capacity in the brain could be increased by allowing more recovery time between cycles. To that end, groups of male mice (n = 4/group) were treated with cycles of 7 days PLX3397 (600 ppm),
followed by 28 days of recovery (Figure 6a ). This time, all three rounds of recovery resulted in repopulation of myeloid cells, showing that the adult brain does have the ability to reconstitute itself with Iba1 + myeloid cells given sufficient recovery time between cycles for repopulation (Figure 6a,b) .
Finally, we investigated whether 28 days of recovery would be sufficient to replenish the myeloid cell compartment in a brain that has been through two short cycles of 7-day treatment/7-day recovery. We found that although the brain fails to repopulate in 7 days after two short cycles of depletion (7-day treatment/7-day recovery), it fully repopulates with Iba1 + cells within 28 days of recovery after the second depletion cycle (Figure 6c,d) , indicating that complete repopulation with myeloid cells, although delayed, is still possible.
| DISCUSSION
We previously demonstrated that microglial elimination via CSF1R
inhibition and the subsequent removal of these antagonists stimulates repopulation of the brain (Elmore et al., 2014) . In a "normal" repopulation event, the brain rapidly repopulates without peripheral contributions, and fully fills with new microglia within just 7 days. These new microglia initially appear reactive but assume homeostatic phenotypes within another 7-14 days . In this study, we sought to determine the limits and kinetics of microglia repopulation events by challenging the adult brain to sequential cycles of microglia depletion and repopulation. We found that the adult brain appears to only have the capacity for a single repopulation event, after which "normal" repopulation then fails to occur, despite the presence of surviving microglia in the brain. However, if the recovery time between, or after, cycles is extended, then the brain can ultimately repopulate with myeloid cells, suggesting that the brain may have multiple mechanisms to repopulate outside of the "normal" repopulation described thus far. For example, other models of microglia depletion using genetic approaches have described a slower mechanism of repopulation that derives from peripheral cells (Varvel et al., 2012) . Furthermore, continuous tamoxifen-induced genetic CSF1R deletion in microglia leads to chronic partial microglial depletion, which over time causes the brain to partly (~50%) fill with peripherally derived macrophages that take up residence within the brain parenchyma (Cronk et al., 2018) . Although our previous studies have shown that with a single "normal" repopulation event following CSF1R inhibition (Elmore et al., 2014) , peripherally derived cells do not infiltrate into the brain,
it is yet to be determined whether peripherally derived cells contribute to the myeloid cell repopulation in either of the extended repopulation events detailed here.
Interestingly, the limited capacity of microglia to repopulate with repeated rapid depletion cycles mirrors findings from OPC's. Administration of cuprizone leads to demyelination of axons through the selective death of oligodendrocytes, and once demyelinated, OPCs then proliferate and differentiate into new oligodendrocytes, effectively remyelinating the axons (Mason et al., 2000; Sachs, Bercury, Popescu, Narayanan, & Macklin, 2014) . Using a model of chronic cuprizone treatment, it has been shown that OPCs become progressively depleted resulting in failed remyelination (Mason et al., 2004) .
Paralleling these observations, we found that with rapid cycles of microglial elimination and recovery (7 days' treatment, 7 days' withdrawal), microglia failed to repopulate a second or third time, suggesting the source of repopulating microglia becomes partially exhausted. Further similarities were also found between oligodendrocyte depletion and subsequent remyelination. Varying the dose and/or time of CSF1R inhibitor treatment affects the extent/speed of microglial depletion. For example, administration of PLX3397 at 290 ppm in chow leads to 50% depletion of microglia within 7 days.
Repopulation following 50% microglial depletion is slow, and does not recover microglial numbers to control levels within 7 days following inhibitor withdrawal. On the other hand, inhibitor withdrawal following >95% microglial elimination, either through 21 days' treatment with PLX3397 at the same dose (290 ppm in chow; Elmore et al., 2014) , or with 7 days' treatment with PLX3397 at 600 ppm in chow, is rapid, with microglial densities exceeded within 7 days. Thus, the brain reacts differently to differing extents of microglial depletion, suggesting a sensing mechanism to mount an appropriate repopulation response, with greater depletion requiring more powerful and rapid repopulation. Similar observations have been made with the remyelination that occurs following cuprizone-mediated demyelination; remyelination only occurs with extensive demyelination rather than incomplete demyelination (Doan et al., 2013) . These similarities to oligodendrocyte repopulation experiments suggest there may be common renewal properties between source cells for microglial repopulation and progenitor cells from the oligodendrocyte lineage. However, it is important to highlight that lineage tracing from OPC's shows that repopulating microglia do not derive from this lineage.
We sought to better understand the signals coordinating successful versus unsuccessful repopulation cycles through whole-brain gene expression profiling, but not surprisingly, the great majority of genes that were differentially expressed between groups with and without microglia, are typically expressed by microglia. As expected, profiling of the microglia-depleted brain revealed a core set of genes that were markedly downregulated with CSF1R inhibitor treatment known to be expressed solely or highly in microglia, and confirm several studies detailing gene expression in microglia extracted from brains (Bennett et al., 2016; Beutner et al., 2013; Butovsky et al., 2014; Chiu et al., 2013; Hickman et al., 2013) . These genes include P2ry12, Tmem119, Fcrls, and Tgfβr1. By profiling total brain RNA rather than isolated microglia, we can further show the relative quantities of these genes in nonmicroglial cells (i.e., their specificity to microglia), as well as confirm that their expression has not been switched on/upregulated by the microglial extraction processes used by the prior studies. Interestingly, we found that OPC-expressed genes are decreased with microglial elimination, supporting the findings of recent studies highlighting the role of adult microglia in OPC population maintenance (Hagemeyer et al., 2017; Janova et al., 2017) . However, we also find that oligodendrocyte-expressed genes are upregulated at the same time, and lineage tracing from OPC's (via PDGFRα-Cre) showed that overall levels of OPC's and their descendants (i.e., oligodendrocytes)
were not altered with microglial elimination or repopulation. Further gene expression profiling of repopulated brains showed that the returning microglia are clearly in an activated state, with a characteristic IFNγ-induced profile, and an upregulation of many proinflammatory cytokines and chemokines. Indeed, our prior results
show that although they initially appear primed to protect against an attack, in the absence of actual pathogens or damage, microglia revert to a resting/surveillant state within 14 days .
The ability to eliminate microglia and then repopulate has potential therapeutic implications. For example, after traumatic brain injuries, microglia become chronically activated, and impede functional recovery (Cherry et al., 2016; Loane, Kumar, Stoica, Cabatbat, & Faden, 2014; Nagamoto-Combs, McNeal, Morecraft, & Combs, 2007; Ramlackhansingh et al., 2011; Smith et al., 1997) . The ability to remove these reactive microglia and then repopulate with fresh microglial cells offers a strategy to resolve neuroinflammation and promote recovery (Rice et al., 2017) , however, there appear to be limits on the frequency and timing of "normal" repopulation events. In conclusion,
we have more fully defined the extent of the adult brain's capacity for renewal of microglial tissue, helping to set the potential opportunities and limits of microglial depletion/repopulation as a therapeutic strategy. 
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